The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey.

Lebret, T; Casas, A; Cavo, M; Woll, P J; Deleplace, C; Kennedy, C; Schoen, P; Jackisch, C

Lebret, T; Casas, A; Cavo, M; Woll, P J; Deleplace, C; Kennedy, C; Schoen, P; Jackisch, C.

Affiliation

Lebret T; Departement d'Urologie, Hôpital Foch, Suresnes, France.
Casas A; Université Versaille St Quentin en Yvelines, Versailles, France.
Cavo M; Servicio de Oncología Médica, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Woll PJ; Departimento di Ematologia e Scienze Oncologiche, Universita di Bologna, Bologna, Italy.
Deleplace C; University of Sheffield Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
Kennedy C; Kantar Health France, Montrouge Cedex, France.
Schoen P; Amgen Ltd, Uxbridge, UK.
Jackisch C; Amgen (Europe) GmbH, Zug, Switzerland.

Eur J Cancer Care (Engl) ; 26(4)2017 Jul.

Article in En | MEDLINE | ID: mdl-27072626

Subject(s)

Bone Density Conservation Agents/therapeutic use; Bone Neoplasms/drug therapy; Diphosphonates/therapeutic use; Neoplasms; Aged; Bone Neoplasms/secondary; Europe; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Patient Safety; Time-to-Treatment; Treatment Outcome

Key words

bisphosphonate; bone metastases; bone-targeted agent; haematological malignancy; skeletal-related event; solid tumour

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Neoplasms / Diphosphonates / Bone Density Conservation Agents / Neoplasms Type of study: Clinical_trials / Guideline / Observational_studies / Qualitative_research Aspects: Patient_preference Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Eur J Cancer Care (Engl) Year: 2017 Document type: Article

Fulltext

XML

PubMed Links

Search on Google